LIVIVO - Search results -

Search results

Result 1 - 10 of total 3276

Search options

Article ; Online: Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Drozd-Sokolowska, Joanna / Gras, Luuk / Koster, Linda / Martino, Rodrigo / Salas, María Queralt / Salmenniemi, Urpu / Zudaire, Teresa / Yañez, Lucrecia / Bellido, Mar / Collin, Matthew / Kaufmann, Martin / Kozlowski, Piotr / Poiré, Xavier / Ferra, Christelle / Sampol, Antònia / Wilson, Keith M O / Cairoli, Anne / Gedde-Dahl, Tobias / Deconinck, Eric /

Mirabile, Milena / Suarez, Felipe / Raj, Kavita / Van Gelder, Michel / Yakoub-Agha, Ibrahim / Tournilhac, Olivier / McLornan, Donal P

Haematologica

2024 Volume 109, Issue 5, Page(s) 1608–1613

MeSH term(s)	Humans ; Hematopoietic Stem Cell Transplantation/methods ; Retrospective Studies ; Leukemia, Prolymphocytic, T-Cell/therapy ; Leukemia, Prolymphocytic, T-Cell/mortality ; Leukemia, Prolymphocytic, T-Cell/diagnosis ; Male ; Female ; Middle Aged ; Transplantation, Autologous ; Aged ; Adult ; Treatment Outcome
Language	English
Publishing date	2024-05-01
Publishing country	Italy
Document type	Letter ; Journal Article
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2023.284359
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.

Martino, Massimo / Macheda, Sebastiano / Aguglia, Umberto / Arcudi, Luciano / Pucci, Giulia / Martino, Bruno / Altomonte, Maria / Rossetti, Antonio Maria / Cusumano, Giuseppa / Russo, Letteria / Imbalzano, Lucrezia / Stelitano, Caterina / Alati, Caterina / Germano', Jessyca / Labate, Demetrio / Amalfi, Vincenzo / Florenzano, Maria Teresa / Morabito, Antonella / Borzumati, Vittoria /

Dattola, Vincenzo / Gattuso, Caterina / Moschella, Antonio / Quattrone, Domenico / Curmaci, Francesco / Franzutti, Claudio / Scappatura, Giuseppe / Rao, Carmelo Massimiliano / Loddo, Viviana / Pontari, Antonella / Pellicano', Maria / Surace, Rosangela / Sanguedolce, Cristina / Naso, Virginia / Ferreri, Anna / Irrera, Giuseppe / Console, Giuseppe / Moscato, Tiziana / Loteta, Barbara / Canale, Filippo Antonio / Trimarchi, Alfonso / Monteleone, Renza / Al Sayyad, Said / Cirrone, Frank / Bruno, Benedetto

Expert opinion on biological therapy

2021 Volume 22, Issue 3, Page(s) 407–421

Abstract: Introduction: Chimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients ... for recognizing and managing the most acute toxicities related to CAR-T cells.: Expert opinion: The development ... of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines ...

Abstract	Introduction: Chimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed. Areas covered: The review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells. Expert opinion: The development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.
MeSH term(s)	Hematologic Neoplasms/therapy ; Humans ; Immunotherapy, Adoptive/adverse effects ; Patient Care Team ; Receptors, Chimeric Antigen ; T-Lymphocytes ; Tumor Microenvironment
Chemical Substances	Receptors, Chimeric Antigen
Language	English
Publishing date	2021-09-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2052501-1
ISSN	1744-7682 ; 1471-2598
ISSN (online)	1744-7682
ISSN	1471-2598
DOI	10.1080/14712598.2021.1974394
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic.

Canale, Filippo A / Martino, Massimo / Porto, Gaetana / Verduci, Chiara / Console, Giuseppe / Irrera, Giuseppe / Loteta, Barbara / Naso, Virginia / Pugliese, Marta / Moscato, Tiziana / Ferreri, Anna / Nappi, Davide / Nicolini, Fabio / Mazza, Massimiliano / Martinelli, Giovanni / Cerchione, Claudio

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

2023 Volume 31, Issue 6, Page(s) 350

Abstract: Purpose: CAR-T programs will burden increasingly on healthcare systems, since the implementation ... quality of life. In this review we propose an innovative, telehealth-based, model for monitoring CAR-T ... patients: this method was used for managing a case of COVID-19 infection occurred two weeks after CAR-T ...

Abstract	Purpose: CAR-T programs will burden increasingly on healthcare systems, since the implementation of these therapies involves: multidisciplinary team collaboration, post-infusion hospitalization with risk of life-threatening toxicities, frequent in hospital visits and prolonged follow-up which heavily influence patients' quality of life. In this review we propose an innovative, telehealth-based, model for monitoring CAR-T patients: this method was used for managing a case of COVID-19 infection occurred two weeks after CAR-T cell infusion. Methods: Several benefits for management of all these aspects of CAR-T programs could be made using telemedicine: for example, telemedicine real-time clinical monitoring could reduce the COVID-19 contagion risks for CAR-T patients. Results: Our experience confirmed feasibility and utility of this approach in a real-life case. We believe that use of telemedicine for CAR-T patients could improve: the logistics of toxicity monitoring (frequent vital sign checks and neurologic assessments), the multidisciplinary team communication (patient selection, specialists consulting, coordination with pharmacists, etc.), the decrease in hospitalization time and the reduction of ambulatory visits. Conclusions: This approach will be fundamental for future CAR-T cell program development, enhancing patients' quality of life and cost-effectiveness for healthcare systems.
MeSH term(s)	Humans ; COVID-19 ; Receptors, Chimeric Antigen ; Pandemics/prevention & control ; Quality of Life ; Telemedicine ; Cell- and Tissue-Based Therapy
Chemical Substances	Receptors, Chimeric Antigen
Language	English
Publishing date	2023-05-25
Publishing country	Germany
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	1134446-5
ISSN	1433-7339 ; 0941-4355
ISSN (online)	1433-7339
ISSN	0941-4355
DOI	10.1007/s00520-023-07811-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3697: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.

Riillo, Caterina / Polerà, Nicoletta / Di Martino, Maria Teresa / Juli, Giada / Hokanson, Craig A / Odineca, Tatjana / Signorelli, Stefania / Grillone, Katia / Ascrizzi, Serena / Mancuso, Antonia / Staropoli, Nicoletta / Caparello, Basilio / Cerra, Maria / Nisticò, Giuseppe / Tagliaferri, Pierosandro / Crea, Roberto / Caracciolo, Daniele / Tassone, Pierfrancesco

Journal of translational medicine

2023 Volume 21, Issue 1, Page(s) 301

Abstract: ... mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells ... in-class bispecific T cell engager (pAXLxCD3ε) against Epithelial Ovarian Cancer (EOC).: Methods ... pAXLxCD3ε T-cell mediated cytotoxicity was evaluated by flow cytometry and bioluminescence. pAXLxCD3ε ...

Abstract	Background: Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer. We describe here the in vitro and in vivo activity of a Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) against Epithelial Ovarian Cancer (EOC). Methods: pAXLxCD3ε T-cell mediated cytotoxicity was evaluated by flow cytometry and bioluminescence. pAXLxCD3ε mediated T-cell infiltration, activation and proliferation were assessed by immunofluorescence microscopy and by flow cytometry. Activity of pAXLxCD3ε was also investigated in combination with poly-ADP ribose polymerase inhibitors (PARPi). In vivo antitumor activity of pAXLxCD3ε was evaluated in immunocompromised (NSG) mice bearing intraperitoneal or subcutaneous EOC xenografts and immunologically reconstituted with human peripheral blood mononuclear cells (PBMC). Results: pAXLxCD3ε induced dose-dependent cytotoxicity by activation of T lymphocytes against EOC cells, regardless of their histologic origin. The addition of PARPi to cell cultures enhanced pAXLxCD3ε cytotoxicity. Importantly, in vivo, pAXLxCD3ε was highly effective against EOC xenografts in two different NSG mouse models, by inhibiting the growth of tumor cells in ascites and subcutaneous xenografts. This effect translated into a significantly prolonged survival of treated animals. Conclusion: pAXLxCD3ε is an active therapeutics against EOC cells providing a rational for its development as a novel agent in this still incurable disease. The preclinical validation of a first-in-class agent opens the way to the development of a new 14Fn3-based scaffold platform for the generation of innovative immune therapeutics against cancer.
MeSH term(s)	Humans ; Mice ; Animals ; Female ; Leukocytes, Mononuclear ; Antibodies, Bispecific/pharmacology ; Antibodies, Bispecific/therapeutic use ; Ovarian Neoplasms/drug therapy ; T-Lymphocytes ; Carcinoma, Ovarian Epithelial ; Cell Line, Tumor ; CD3 Complex
Chemical Substances	Antibodies, Bispecific ; CD3 Complex
Language	English
Publishing date	2023-05-04
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2118570-0
ISSN	1479-5876 ; 1479-5876
ISSN (online)	1479-5876
ISSN	1479-5876
DOI	10.1186/s12967-023-04101-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.

British journal of haematology

2023 Volume 204, Issue 2, Page(s) 555–560

Abstract: ... non-haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T ...

Abstract	UMG1 is a unique epitope of CD43, not expressed by normal cells and tissues of haematopoietic and non-haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T lymphocytes. By immunohistochemistry analysis of tissue microarray and pathology slides, we found high UMG1 expression in 20%-24% of diffuse large B-cell lymphomas (DLBCLs), including highly aggressive BCL2
MeSH term(s)	Humans ; T-Lymphocytes/metabolism ; Lymphoma, Large B-Cell, Diffuse/pathology ; Immunohistochemistry
Language	English
Publishing date	2023-11-14
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.19183
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.

Novelli, Silvana / Bento, Leyre / Garcia, Irene / Prieto, Laura / López, Lucía / Gutierrez, Gonzalo / Hernani, Rafael / Pérez, Ariadna / Esquirol, Albert / Solano, Carlos / Bastos, Mariana / Dorado, Nieves / Rodríguez, Nancy / Rodríguez, Guillermo / Piñana, Jose L / Montoro, Juan / Herrera, Pilar / Luna, Alejandro / Parody, Rocío /

Martín, Carmen / García, Estefanía / López, Oriana / Heras, Inmaculada / Zanabili, Joud / Moraleda, Jose M / Yañez, Lucrecia / Gutierrez, Antonio / Zudaire, Teresa / Córdoba, Raúl / Varela, Rosario / Ferra, Christelle / Martínez, Joaquin / Martínez, Carmen / Gonzalez-Barca, Eva / Martino, Rodrigo / Caballero, Dolores

Transplantation and cellular therapy

2021 Volume 27, Issue 6, Page(s) 493.e1–493.e8

Abstract: Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia ... treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic ... stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias ...

Abstract	Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia, current therapies, even the most innovative ones, are still far from ensuring its cure. The only treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Español de Linfoma y Trasplante de Médula Ósea/Grupo Español de Trasplante Hematopoyético y Terapia Celular) over the past 25 years. As a secondary objective, we analyzed the results of alloSCT from haploidentical donors. We performed a retrospective analysis of all patients who received an alloSCT in Spanish centers (n = 201) from September 1995 to August 2018. The 2-year overall survival (OS) and disease-free survival (DFS) were 65.5% and 58.2%, respectively. The univariate for OS and DFS showed statistically different hazard ratios for conditioning intensity, response pre-alloSCT, comorbidity index, donor/receptor cytomegalovirus status and Eastern Cooperative Oncology Group (ECOG) pre-alloSCT, but only a better ECOG pre-alloSCT remained significant in the multivariate analysis. There was an increased incidence of relapse in those patients who did not develop chronic graft-versus-host disease (GVHD) and an increased risk of death in those developing moderate to severe acute GVHD. The 1-year nonrelapse mortality was 21.9% and was mainly due to GVHD (30%) and bacterial infections (17%). When comparing unrelated donors with haploidentical donors, we found similar results in terms of OS and DFS. There was, however, a reduction of acute GVHD in the haploidentical group (P = .04) and trend to a reduction of chronic GVHD. In conclusion, alloSCT is the only curative option for most aggressive T cell neoplasias. Haploidentical donors offer similar results to related donors in terms of survival with a reduction of acute GVHD.
MeSH term(s)	Hematopoietic Stem Cell Transplantation ; Humans ; Killer Cells, Natural ; Neoplasm Recurrence, Local ; Registries ; Retrospective Studies ; Transplantation Conditioning
Language	English
Publishing date	2021-03-15
Document type	Journal Article
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2021.03.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: iAstrocytes do not restrain T cell proliferation in vitro.

Colombo, Emanuela / De Angelis, Anthea / Bassani, Claudia / Ruffini, Francesca / Ottoboni, Linda / Garzetti, Livia / Finardi, Annamaria / Martino, Gianvito / Furlan, Roberto / Farina, Cinthia

BMC neuroscience

2023 Volume 24, Issue 1, Page(s) 33

Abstract: The cross-talk between T cells and astrocytes occurring under physiological and, even more ... of astrocytes differing for age, sex, and species. Mouse neonatal astrocytes enhanced T cell vitality ... but suppressed T lymphocyte proliferation in response to mitogenic stimuli or myelin antigens, regardless ...

Abstract	The cross-talk between T cells and astrocytes occurring under physiological and, even more, neuroinflammatory conditions may profoundly impact the generation of adaptive immune responses in the nervous tissue. In this study, we used a standardized in vitro co-culture assay to investigate the immunomodulatory properties of astrocytes differing for age, sex, and species. Mouse neonatal astrocytes enhanced T cell vitality but suppressed T lymphocyte proliferation in response to mitogenic stimuli or myelin antigens, regardless of the Th1, Th2 or Th17 T cell phenotype. Studies comparing glia cells from adult and neonatal animals showed that adult astrocytes were more efficient in inhibiting T lymphocyte activation than neonatal astrocytes, regardless of their sex. Differently from primary cultures, mouse and human astrocytes derived from reprogrammed fibroblasts did not interfere with T cell proliferation. Overall, we describe a standardized astrocyte-T cell interaction in vitro assay and demonstrate that primary astrocytes and iAstrocytes may differ in modulating T cell function.
MeSH term(s)	Animals ; Humans ; Mice ; Astrocytes ; Cell Proliferation ; Lymphocyte Activation ; Neuroglia ; Th17 Cells ; Male ; Female
Language	English
Publishing date	2023-06-07
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2041344-0
ISSN	1471-2202 ; 1471-2202
ISSN (online)	1471-2202
ISSN	1471-2202
DOI	10.1186/s12868-023-00806-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Integrating CAR-T cell therapy into the management of DLBCL: what we are learning.

Martino, Massimo / Canale, Filippo Antonio / Porto, Gaetana / Verduci, Chiara / Utano, Giovanna / Policastro, Giorgia / Germanò, Jessyca / Alati, Caterina / Santoro, Ludovica / Imbalzano, Lucrezia / Pitea, Martina

Expert opinion on biological therapy

2023 Volume 23, Issue 12, Page(s) 1277–1285

Abstract: Introduction: Chimeric Antigen Receptor ;(CAR) T cells therapies have become part of the standard ... of CAR-T therapies is that there are no comparative clinical trials, although many publications based ... of the commercialization of CAR-T, some points still need to be fully clarified. Healthcare professionals have questions ...

Abstract	Introduction: Chimeric Antigen Receptor ;(CAR) T cells therapies have become part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The weakness of CAR-T therapies is that there are no comparative clinical trials, although many publications based on real-life data have confirmed the results obtained in pivotal studies. After several years of the commercialization of CAR-T, some points still need to be fully clarified. Healthcare professionals have questions about identifying patients who may benefit from therapy. There are aspects inherent in the accessibility of care related to improved relationships between CAR-T-delivering and referral centers. Areas covered: Open questions are inherent in the salvage and bridge therapy, predictive criteria for response and persistence of CAR-T after infusion. Managing toxicities remain a top priority and one of the points on which further knowledge is needed. Expert opinion: This review aims to describe the current landscape of CAR-T cells in DLBCL, outline their outcomes and toxicities, and explain the outstanding questions that remain to be addressed.
MeSH term(s)	Humans ; Receptors, Chimeric Antigen ; Immunotherapy, Adoptive/adverse effects ; Lymphoma, Large B-Cell, Diffuse/therapy ; Lymphoma, Non-Hodgkin ; Cell- and Tissue-Based Therapy
Chemical Substances	Receptors, Chimeric Antigen
Language	English
Publishing date	2023-12-28
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2052501-1
ISSN	1744-7682 ; 1471-2598
ISSN (online)	1744-7682
ISSN	1471-2598
DOI	10.1080/14712598.2023.2292634
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Magnetic resonance imaging at 9.4 T: the Maastricht journey.

Ivanov, Dimo / De Martino, Federico / Formisano, Elia / Fritz, Francisco J / Goebel, Rainer / Huber, Laurentius / Kashyap, Sriranga / Kemper, Valentin G / Kurban, Denizhan / Roebroeck, Alard / Sengupta, Shubharthi / Sorger, Bettina / Tse, Desmond H Y / Uludağ, Kâmil / Wiggins, Christopher J / Poser, Benedikt A

Magma (New York, N.Y.)

2023 Volume 36, Issue 2, Page(s) 159–173

Abstract: The 9.4 T scanner in Maastricht is a whole-body magnet with head gradients and parallel RF transmit ... but it has also been used for anatomical and diffusion imaging. 9.4 T offers increases in sensitivity and ... constraints set by RF power deposition, are exacerbated compared to 7 T. This article reviews some of the 9.4 ...

Abstract	The 9.4 T scanner in Maastricht is a whole-body magnet with head gradients and parallel RF transmit capability. At the time of the design, it was conceptualized to be one of the best fMRI scanners in the world, but it has also been used for anatomical and diffusion imaging. 9.4 T offers increases in sensitivity and contrast, but the technical ultra-high field (UHF) challenges, such as field inhomogeneities and constraints set by RF power deposition, are exacerbated compared to 7 T. This article reviews some of the 9.4 T work done in Maastricht. Functional imaging experiments included blood oxygenation level-dependent (BOLD) and blood-volume weighted (VASO) fMRI using different readouts. BOLD benefits from shorter T
MeSH term(s)	Magnetic Resonance Imaging/methods
Language	English
Publishing date	2023-04-20
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	1160826-2
ISSN	1352-8661 ; 0968-5243
ISSN (online)	1352-8661
ISSN	0968-5243
DOI	10.1007/s10334-023-01080-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3788: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

Saad, Ayman / Lamb, Lawrence / Wang, Tao / Hemmer, Michael T / Spellman, Stephen / Couriel, Daniel / Alousi, Amin / Pidala, Joseph / Abdel-Azim, Hisham / Agrawal, Vaibhav / Aljurf, Mahmoud / Beitinjaneh, Amer M / Bhatt, Vijaya Raj / Buchbinder, David / Byrne, Michael / Cahn, Jean-Yves / Cairo, Mitchell / Castillo, Paul / Chhabra, Saurabh /

Diaz, Miguel Angel / Farhan, Shatha / Floisand, Yngvar / Frangoul, Hadar A / Gadalla, Shahinaz M / Gajewski, James / Gale, Robert Peter / Gandhi, Manish / Gergis, Usama / Hamilton, Betty Ky / Hematti, Peiman / Hildebrandt, Gerhard C / Kamble, Rammurti T / Kanate, Abraham S / Khandelwal, Pooja / Lazaryan, Aleksandr / MacMillan, Margaret / Marks, David I / Martino, Rodrigo / Mehta, Parinda A / Nishihori, Taiga / Olsson, Richard F / Patel, Sagar S / Qayed, Muna / Rangarajan, Hemalatha G / Reshef, Ran / Ringden, Olle / Savani, Bipin N / Schouten, Harry C / Schultz, Kirk R / Seo, Sachiko / Shaffer, Brian C / Solh, Melhem / Teshima, Takanori / Urbano-Ispizua, Alvaro / Verdonck, Leo F / Vij, Ravi / Waller, Edmund K / William, Basem / Wirk, Baldeep / Yared, Jean A / Yu, Lolie C / Arora, Mukta / Hashmi, Shahrukh

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2019 Volume 25, Issue 9, Page(s) 1875–1883

Abstract: Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences ... 8-matched unrelated donor (MUD). We excluded ex vivo and in vivo T cell-depleted transplantations ...

Abstract	Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). We excluded ex vivo and in vivo T cell-depleted transplantations. Correlative analysis was performed between CD3
MeSH term(s)	Acute Disease ; Adolescent ; Adult ; Allografts ; CD4-CD8 Ratio ; CD4-Positive T-Lymphocytes ; CD8-Positive T-Lymphocytes ; Disease-Free Survival ; Female ; Graft vs Host Disease/blood ; Graft vs Host Disease/mortality ; Graft vs Host Disease/prevention & control ; HLA Antigens ; Humans ; Leukemia/blood ; Leukemia/mortality ; Leukemia/therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/blood ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Peripheral Blood Stem Cell Transplantation ; Recurrence ; Survival Rate
Chemical Substances	HLA Antigens
Language	English
Publishing date	2019-05-11
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2019.05.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito